Druggability Assessment for Selected Serine Proteases in a Pharmaceutical Industry Setting.

ChemMedChem

Bayer AG, Research & Development, Pharmaceuticals, 42096, Wuppertal, Germany.

Published: November 2020

Target druggability assessment is an integral part of the early target characterization and selection process in pharmaceutical industry. Here, we investigate a set of five different serine proteases from the blood coagulation cascade. The aim of this study is twofold. Firstly, leveraging the wealth of available in-house high-throughput screening (HTS) data, we analyze HTS hit rates and discuss their predictive value for the development of small molecule (SMOL) candidates. Purely structure-activity relationship (SAR) based druggability ratings are compared with computational protein-structure based druggability assessments. Secondly, we evaluate the impact of using conformational ensembles from molecular dynamics (MD) simulations instead of single static crystal structures as basis for computational druggability assessments. Based on this study, we recommend incorporating molecular dynamics routinely into the early target characterization process, especially if only a single X-ray structure is available.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cmdc.202000425DOI Listing

Publication Analysis

Top Keywords

druggability assessment
8
serine proteases
8
pharmaceutical industry
8
early target
8
target characterization
8
based druggability
8
druggability assessments
8
molecular dynamics
8
druggability
5
assessment selected
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!